Committee Action
On June 14, 2023, the Subcommittee on Health held a hearing
on H.R. 2365. The title of the hearing was ``Examining
Proposals that Provide Access to Care for Patients and Support
Research for Rare Diseases.'' The Subcommittee received
testimony from:
Dr. Elizabeth Cherot, MD, MBA, Senior Vice
President and Chief Medical Health Officer, March of
Dimes;
Dr. Alexis A. Thompson, MD, MPH, Chief of
Division of Hematology, Elias Schwartz MD Endowed Chair
in Hematology, Children's Hospital of Philadelphia,
Professor of Pediatrics, University of Pennsylvania
Perelman School of Medicine;
Dr. Meredithe McNamara, MD, MS, FAAP,
Assistant Professor, Yale School of Medicine;
Dr. Miriam Grossman, MD, Child, Adolescent,
and Adult Psychiatrist;
Mr. George Manahan, Parkinson's Advocate and
Patient; and,
Mr. Kevin O'Connor, Assistant to the General
President for Government Affairs and Political Action,
International Association of Fire Fighters.
On July 13, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 2365, without amendment, to
the full Committee by a voice vote. On December 5 and 6, 2023,
the full Committee on Energy and Commerce met in open markup
session and ordered H.R. 2365, as amended, favorably reported
to the House by a record vote of 47 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
prevent, diagnose, treat, and cure Parkinson's disease and
other neurodegenerative Parkinsonisms and related diseases.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2365 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 2365:
On June 14, 2023, the Subcommittee on Health
held a hearing on H.R. 2365. The title of the hearing
was ``Examining Proposals that Provide Access to Care
for Patients and Support Research for Rare Diseases.''
The Subcommittee received testimony from:
Dr. Elizabeth Cherot, MD, MBA,
Senior Vice President and Chief Medical Health
Officer, March of Dimes;
Dr. Alexis A. Thompson, MD, MPH,
Chief of Division of Hematology, Elias Schwartz
MD Endowed Chair in Hematology, Children's
Hospital of Philadelphia, Professor of
Pediatrics, University of Pennsylvania Perelman
School of Medicine;
Dr. Meredithe McNamara, MD, MS,
FAAP, Assistant Professor, Yale School of
Medicine;
Dr. Miriam Grossman, MD, Child,
Adolescent, and Adult Psychiatrist;
Mr. George Manahan, Parkinson's
Advocate and Patient; and,
Mr. Kevin O'Connor, Assistant to
the General President for Government Affairs
and Political Action, International Association
of Fire Fighters.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2365 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
Pursuant to section 5(b) of the Federal Advisory Committee
Act (FACA), the Committee finds that new subsection 399OO(e) of
the Public Health Service Act, as provided in section 2 of H.R.
2365, does establish or authorize the establishment of an
advisory committee as defined in section 3(2) of FACA. The
Committee does not find that the functions of the proposed
advisory committee are being or could be performed by one or
more agencies or by an advisory committee already in existence,
or by enlarging the mandate of an existing advisory committee.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the ``Dr.
Emmanuel Bilirakis National Plan to End Parkinson's Act''.
Section 2. National Parkinson's Project
Section 2 would add a new section (``sec. 399OO. National
Parkinson's Project'') to the Public Health Service Act
directing the Secretary of the Department of Health and Human
Services (HHS) to carry out the National Parkinson's Project.
Section 2 would define the term ``Parkinson's'' to mean (1)
Parkinson's disease; and (2) all other neurodegenerative
Parkinsonisms, including multiple system atrophy, corticobasal
degeneration, progressive supranuclear palsy, and Parkinson's-
related dementia.''
New subsection (c) would direct the Secretary to (1)
create, maintain, and update an integrated national plan to
prevent, diagnose, treat, and cure Parkinson's, ameliorate
symptoms, and slow or stop progression; (2) carry out an annual
assessment; (3) provide specified information; (4) coordinate
Parkinson's related research and services across all Federal
agencies; (5) encourage the development of safe and effective
treatments, strategies, and other approaches to prevent,
diagnose, treat, and cure Parkinson's, ameliorate symptoms, and
slow or stop progression; (6) improve both the early diagnosis
of Parkinson's and coordination of the care and treatment of
individuals with Parkinson's; (7) review the impact of
Parkinson's on the physical, mental, and social health of
individuals living with Parkinson's and their caregivers and
families; (8) to the extent possible--coordinate with
international bodies to integrate and inform the mission to
prevent, diagnose, treat, and cure Parkinson's, ameliorate
symptoms, and slow or stop progression globally; and (9) to the
extent practicable--collaborate with other entities to prevent
duplication of existing research activities for related
disorders.
New subsection (d) describes the annual assessment that the
Secretary must carry out within 24 months of the date of
enactment and annually thereafter. This shall include an
assessment of the Nation's progress in preparing for and
responding to the escalating burden of Parkinson's, including
(1) recommendations for priority actions, and (2) a description
of steps planned or already taken to implement such
recommendations--including whether such recommendation can be
implemented under existing law.
The Committee anticipates that the Secretary will provide
to the Committee on Energy and Commerce a copy of the
assessment--both electronically and in paper format--promptly
upon completion of the assessment and subsequent assessments.
New subsection (e) would direct the Secretary to establish
and maintain an Advisory Council on Parkinson's Research, Care,
and Services to advise the Secretary on Parkinson's-related
issues. The Advisory Council shall be comprised of federal and
non-federal stakeholders, and shall convene meetings as
specified. The Advisory Council shall provide regular reports,
as specified, including current activities, recommendations,
priority actions, and implementation steps to improve efforts
related to the prevention, diagnosis, treatment, and curing of
Parkinson's and related diseases. The Advisory Council shall
terminate at the end of calendar year 2035.
New subsection (f) would direct each Federal department and
agency that has information relating to Parkinson's to share
such information with the Secretary consistent with the
statutory obligations of such department or agency regarding
disclosure of information, as necessary to enable the Secretary
to complete the required annual report to Congress.
New subsection (g) provides that this new section of the
Public Health Service Act, regarding the ``National Parkinson's
Project'' shall cease to be effective at the end of calendar
year 2035.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (new matter is
printed in italics and existing law in which no change is
proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
PART W--PARKINSON'S AND RELATED DISORDERS
SEC. 399OO. NATIONAL PARKINSON'S PROJECT.
(a) Definition of Parkinson's.--In this section, the term
``Parkinson's'' means--
(1) Parkinson's disease; and
(2) all other neurodegenerative Parkinsonisms,
including multiple system atrophy, corticobasal
degeneration, progressive supranuclear palsy, and
Parkinson's-related dementia.
(b) Establishment.--The Secretary shall carry out a national
project, to be known as the National Parkinson's Project
(referred to in this section as the ``Project''), to prevent,
diagnose, treat, and cure Parkinson's.
(c) Activities Carried Out Through Project.--In carrying out
the Project, the Secretary shall--
(1) create, maintain, and periodically update an
integrated national plan to prevent, diagnose, treat,
and cure Parkinson's, ameliorate symptoms, and slow or
stop progression;
(2) carry out the annual assessment under subsection
(d);
(3) provide information, including--
(A) an estimate of the level of current
Federal investment in preventing, diagnosing,
treating, and curing Parkinson's, ameliorating
symptoms, and slowing or stopping progression;
and
(B) if applicable, an estimate of the
investment necessary to prevent, diagnose,
treat, and cure Parkinson's, ameliorate
symptoms, and slow or stop progression;
(4) coordinate research and services across all
Federal agencies related to Parkinson's;
(5) encourage the development of safe and effective
treatments, strategies, and other approaches to
prevent, diagnose, treat, and cure Parkinson's,
ameliorate symptoms, and slow or stop progression;
(6) improve the--
(A) early diagnosis of Parkinson's; and
(B) coordination of the care and treatment of
individuals with Parkinson's;
(7) review the impact of Parkinson's on the physical,
mental, and social health of individuals living with
Parkinson's and their caregivers and families;
(8) coordinate with international bodies, to the
extent possible, to integrate and inform the mission to
prevent, diagnose, treat, and cure Parkinson's,
ameliorate symptoms, and slow or stop progression
globally; and
(9) to the extent practicable, collaborate with other
entities to prevent duplication of existing research
activities for related disorders.
(d) Annual Assessment.--Not later than 24 months after the
date of enactment of this section, and annually thereafter, the
Secretary shall carry out an assessment of the Nation's
progress in preparing for, and responding to, the escalating
burden of Parkinson's, including--
(1) recommendations for priority actions based on the
assessment;
(2) a description of any steps that are planned or
have already been taken to implement such
recommendations, including whether such recommendations
can be implemented under existing law; and
(3) such other items as the Secretary determines
appropriate.
(e) Advisory Council.--
(1) In general.--The Secretary shall establish and
maintain an Advisory Council on Parkinson's Research,
Care, and Services (referred to in this section as the
``Advisory Council'') to advise the Secretary on
Parkinson's-related issues.
(2) Membership.--
(A) Federal members.--The Advisory Council
shall be comprised of experts, to be appointed
by the Secretary, who collectively are from
various backgrounds and perspectives, including
at least one member from each of--
(i) the Centers for Disease Control
and Prevention;
(ii) the Administration on Community
Living;
(iii) the Centers for Medicare &
Medicaid Services;
(iv) the National Institutes of
Health;
(v) the Agency for Healthcare
Research and Quality;
(vi) the Department of Veterans
Affairs;
(vii) the Food and Drug
Administration;
(viii) the National Science
Foundation;
(ix) the Department of Defense;
(x) the Environmental Protection
Agency;
(xi) the Office of Minority Health;
(xii) the Indian Health Service;
(xiii) the Surgeon General of the
Public Health Service; and
(xiv) other relevant Federal
departments and agencies as determined
by the Secretary.
(B) Non-federal members.--In addition to the
members listed in subparagraph (A), the
Advisory Council shall include 10 expert
members, to be appointed by the Secretary, who
shall include representatives of minority
communities, communities disproportionately
affected by Parkinson's, and communities
underrepresented in Parkinson's research, who
shall each be from outside the Federal
Government, and who shall include--
(i) 2 Parkinson's patient advocates,
at least 1 of whom is living with
young-onset Parkinson's;
(ii) 1 Parkinson's family caregiver;
(iii) 1 health care provider;
(iv) 2 biomedical researchers with
Parkinson's-related expertise in basic,
translational, clinical, or drug
development science;
(v) 1 movement disorder specialist
who treats Parkinson's patients;
(vi) 1 dementia specialist who treats
Parkinson's patients; and
(vii) 2 representatives from
nonprofit organizations that have
demonstrated experience in Parkinson's-
related research or Parkinson's-related
patient care and other services.
(C) Representation.--The Secretary shall
ensure that the members of the Advisory Council
are collectively representative of agencies,
professions, individuals, and entities
concerned with, or affected by, activities
under this section.
(3) Meetings.--
(A) Frequency.--The Advisory Council shall
meet--
(i) at least once each quarter during
the 2-year period beginning on the date
on which the Advisory Council is
established; and
(ii) at the Secretary's discretion
after such period.
(B) Annual research meeting.--Not later than
24 months after the date of enactment of this
section, and every year thereafter, the
Advisory Council shall convene a meeting of
Federal and non-Federal organizations to
discuss Parkinson's research.
(C) Open meetings.--The meetings under
subparagraphs (A) and (B) shall be open to the
public.
(4) Annual report.--Not later than 18 months after
the date of enactment of this section, and every year
thereafter, the Advisory Council shall provide to the
Secretary and Congress a report containing--
(A) a list of all federally-funded efforts in
Parkinson's research, prevention, diagnosis,
treatment, clinical care, and institutional-,
home-, and community-based programs and the
outcomes of such efforts;
(B) recommendations for priority actions to
expand, eliminate, coordinate, refocus,
streamline, or condense Federal programs based
on each program's performance, mission, scope,
and purpose;
(C) recommendations to--
(i) reduce the financial impact of
Parkinson's on families living with
Parkinson's;
(ii) improve health outcomes for, and
the quality of life of, individuals
living with Parkinson's;
(iii) prevent Parkinson's, ameliorate
symptoms, and slow or stop progression;
(iv) improve the quality of care
provided to beneficiaries with
Parkinson's who receive coverage
through a federally-funded health care
program, such as the Medicare program
under title XVIII of the Social
Security Act or the Medicaid program
under title XIX of such Act;
(v) research the association between
environmental triggers and Parkinson's
to help reduce exposure to potential
triggers; and
(vi) research and better understand
the underlying factors contributing to
Parkinson's;
(D) priority actions to improve all
federally-funded efforts in Parkinson's
research, prevention, diagnosis, treatment,
clinical care, and institutional-, home-, and
community-based programs;
(E) an evaluation of the implementation,
including outco